ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
FS Development Corporation II

FS Development Corporation II (FSII)

9.80
0.00
(0.00%)
Closed February 01 4:00PM
0.00
0.00
(0.00%)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
9.80
Bid
9.77
Ask
9.87
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
9.80
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

FSII Latest News

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million...

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

Proposed merger heads to shareholder vote on December 23rd as ongoing Phase I trial shows potential for unboosted oral regimen In advance of the shareholder vote for the business combination...

FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021

FS Development Corp. II, a Delaware corporation (the “Company”) (Nasdaq: FSII), announced today that its registration statement on Form S-4 (File No. 333-258442) (as amended, the “Registration...

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections

CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating...

Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors

CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to...

Pardes Biosciences & FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Adv...

Leading institutional and strategic investors commit $75 million through a common stock private investment in public equity (“PIPE”) led by Foresite Capital, as well as Gilead Sciences, RA...

FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offering

FS Development Corp. II (the “Company”) announced today that it priced its initial public offering of 17,500,000 shares of Class A common stock at $10.00 per share. The shares will be listed on...

Tokyo Electron Limited Completes Acquisition of FSI International, Inc.

Tokyo Electron Limited Completes Acquisition of FSI International, Inc. PR Newswire TOKYO, Oct. 11, 2012 TOKYO, Oct. 11, 2012 /PRNewswire/ -- Tokyo Electron Limited ("Tokyo Electron";...

Tokyo Electron Limited Announces Completion of Tender Offer for FSI International, Inc.

Tokyo Electron Limited Announces Completion of Tender Offer for FSI International, Inc. PR Newswire TOKYO, Oct. 11, 2012 TOKYO, Oct. 11, 2012 /PRNewswire/ -- Tokyo Electron Limited ("Tokyo...

Tokyo Electron Limited Extends Tender Offer to Acquire FSI International, Inc.

Tokyo Electron Limited Extends Tender Offer to Acquire FSI International, Inc. PR Newswire TOKYO, Sept. 25, 2012 TOKYO, Sept. 25, 2012 /PRNewswire/ -- Tokyo Electron Limited ("Tokyo Electron";...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

FSII - Frequently Asked Questions (FAQ)

What is the current FS Development Corporati... share price?
The current share price of FS Development Corporati... is $ 9.80
What is the 1 year trading range for FS Development Corporati... share price?
FS Development Corporati... has traded in the range of $ 0.00 to $ 0.00 during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TCTMTCTM Kids IT Education Inc
$ 0.764
(321.87%)
731.1M
REBNReborn Coffee Inc
$ 3.31
(63.05%)
55.54M
FCUVFocus Universal Inc
$ 5.87
(56.62%)
1.73M
SOPASociety Pass Inc
$ 1.54
(56.50%)
13.87M
CYCNCyclerion Therapeutics Inc
$ 3.92
(54.33%)
82.57M
ENVBEnveric Biosciences Inc
$ 2.0899
(-46.41%)
1.57M
NIVFNewGenIvf Group Ltd
$ 0.1489
(-42.51%)
14.8M
GLSTGlobal Star Acquisition Inc
$ 8.83
(-39.10%)
23.89k
PRPHProPhase Labs Inc
$ 0.2633
(-38.02%)
872.46k
SPGCSacks Parente Golf Inc
$ 0.5601
(-37.86%)
7.27M
TCTMTCTM Kids IT Education Inc
$ 0.764
(321.87%)
729.72M
NVDANVIDIA Corporation
$ 120.07
(-3.67%)
388.54M
RIMEAlgorhythm Holdings Inc
$ 0.02565
(5.12%)
338.75M
BHATBlue Hat Interactive Entertainment Technology
$ 0.0355
(-11.25%)
236.29M
CLEUChina Liberal Education Holdings Ltd
$ 0.1938
(30.77%)
234.8M

Discussion

View Full Feed
No Posts Found

Your Recent History

Delayed Upgrade Clock